エピソード
-
What if we could replace mouse model control groups with a virtual equivalent? What would that mean for drug development in terms of cost, time, and animal model reduction? To answer, I am joined by Charles River associate director Laura Lotfi and Guillemette Duchateau-Nguyen from F. Hoffmann-La Roche Ltd, Pharmaceutical Sciences - Roche Innovation Center Basel. Listen now to learn how close we are to replacing some physical models with 1's and 0's.
-
Alex Sargent, Director of Process Development at Charles River in our Cell and Gene Therapy department, joins me to discuss the work he and his partner put into developing an algorithm to make his job faster and easier. How can you train a computer to accurately sift through the mountains of data generated in drug development? Listen now to find out!
-
エピソードを見逃しましたか？
-
There have been many articles recently about cellular agriculture, or lab-grown meat products. But what happens when a company takes a practical approach to this science fiction concept? Joining me are Charles River's Steven Miklasz from our Biologics Testing Solutions team; and Ramsey Foty, Scientific Director for Fork & Good, a cultivated meat company, to discuss how the sausage is made!
-
This month I am joined by Benjamin Oakes, scientist, entrepreneur, and co-founder of Scribe Therapeutics. He studied at UC Berkeley, working in the Doudna Lab and Savage Lab during the earliest days of CRISPR. We discuss his personal vision for the future of CRISPR, encouraging advances in the field, and the first ever drug approval for a CRISPR based therapy.
-
Norm Wainwright and Foster Jordan have been immersed in the field of limulus amebocyte lysate (LAL) testing for decades, and have seen the progress and refinement of this crucial safety test. With the 20th anniversary of Charles River's Endosafe Cartridge and the recent introduction of recombinant alternatives, we look back at the past and future of endotoxin testing.
-
I am joined by four experts in their field to discuss what will be hot in rare diseases, drug discovery, artificial intelligence, and animal models in 2024.
-
Molly Dupre, a lab assistant at Charles River's Reno site, was recently diagnosed with Niemann-Pick Type B/ Acid Sphingomyelinase Deficiency. After years of waiting, doctor's visits, and tests, she could finally put a name to the condition that flared up after the birth of her son. But what came next? She joins me to tell her story.
-
Senior Principal Scientific Advisor Stan Spence joins me to discuss off-target liability: what happens when a drug misses its target? What are the risks to the patient if the off-target effects aren't caught early? Has there ever been an example of an off-target effect being beneficial to the patient? Find out here!
-
Rachel Kiserow and Susan Desmond have joined us year after year as part of Eureka's Breast Cancer Roundtable. This year, they wanted to share what happens after - after the treatments, after remission - life after cancer.
-
For this episode, I am joined by Charles River's Doug Botkin and Pure Microbiology's Abby Roth to discuss the 2012 NECC meningitis outbreak. Doug and Abby bring their background in microbiology to explain how it happened, and how we can prevent such tragedies in the future.
-
Charles River experts Justin Bryans and Elizabeth Anderson join me for a spirited discussion of where we are now in oncology research. Could we ever see a world without cancer?
-
Manufacturing gene therapies is a hot topic in the pharma field, on both the supplier and the client ends. Joining me to discuss this issue is Charles River Associate Director of Gene Therapy, Andrew Frazer, and Purespring Therapeutics' VP of Chemistry, Manufacturing and Controls, Amanda Weiss.
-
Dr. Lauren Black and Dr. Monkol Lek are both committed to the research and advancement of rare disease treatments. But when you are trying to treat just one patient, what can you learn that could help many more? We discuss the importance of n-of-1 studies, not just for that one patient and their families, but for anyone who might someday need a rare cure.
-
Through his own first-hand experience, Charles River Senior Director of Global Talent Acquisition Michael Hakeem knows the importance of diversity in hiring. He joins us this Pride Month to talk about his experiences and his insight into a thoughtful approach to recruiting for a company as large as Charles River.
-
Jesse McCool from Wheeler Bio and Ian Wyllie from Charles River's RightSource℠ program join me to discuss the manufacturing of biologics from both ends: getting from development to first in human, and quality control.
-
Mycologist Ziva Abraham discusses fungal detection and identification in cleanrooms, and whether the TV show The Last of Us portrays a realistic fungal zombie apocalypse.
-
This month I am joined by Romaine Wright, Program Manager for Learning and Development for Charles River, to discuss allyship in the workplace. How can we use whatever privileges we have to help our colleagues and build a more diverse workforce?
-
This month I am joined by Dr. Elise Lewis, principal director of toxicology for Charles River's Horsham, Pennsylvania site. As a woman of color in the scientific field, she is passionate about mentoring the scientists of tomorrow.
She can also be seen in this interview with Fox 29 Philadelphia: https://www.fox29.com/video/902459
-
In vivo models have been the drug safety standard for as long as there have been drug safety standards. With mounting data proving the worth of in vitro models, could there be a future where we will not need in vivo? I am joined by Anjli Venkateswaran, Director of Strategic Partnerships for Charles River, to discuss this trending topic.
-
This year Charles River celebrated its 75th anniversary. To help me reminisce about how far the company and science in general have come in that time, I invited Chief Commercial Officer Bill Barbo to chat. He started at Charles River in 1982 as a scientist, and has seen the company grow and change along with advances in science.
- もっと表示する
